Avacta Group plc Appoints Tony Gardiner As Chief Financial Officer

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it has appointed Tony Gardiner as Group Chief Financial Officer. Mr Gardiner will join the Group on 4 January 2016.

As announced on 7 July 2015, Tim Sykes, who has held the part-time role of Chief Financial Officer since IPO, informed the Board he wished to step down from this role to pursue other business interests. Tim leaves the Group today and Craig Slater, Chief Operating Officer, will serve as Interim Chief Financial Officer with immediate effect until 4 January when Tony joins.

Between 2007 and 2011, Tony was the Chief Financial Officer of AIM listed Fusion IP plc, an IP commercialisation company, which was subsequently acquired by IP Group plc in 2014. Here, he played a key role in supporting the Chief Executive Officer in growing the business and oversaw all finance activities as well as directly supporting life sciences and health technology companies in Fusion's portfolio.

Tony joins Avacta from AHR an international architecture and building consultancy practice where he has held the role of Finance Director since 2011. During his time at AHR, Tony oversaw the financial and legal demerger of the practice from Aedas, an international design practice and, following this, the financial restructuring of the practice.

Tony has also held senior finance roles within Eversheds LLP, KCOM Group Plc, Eldon Electric Ltd and Hickson International Plc.

Dr Alastair Smith, Chief Executive Officer of Avacta, said:

"We are delighted that Tony will be joining Avacta at such an important time in our development. Tony's wealth of experience, in particular his time as Chief Financial Officer of Fusion IP plc, a role in which he was involved with numerous health technology and life sciences businesses, will be of great value to the Group. We look forward to working with him as part of the senior leadership team as we continue to progress the development and commercialisation of our Affimer® platform to create value for our shareholders.

"We would once again like to thank Tim for his contribution to the Group over the years and wish him well for the future. We would also like to thank Craig for serving as Chief Financial Officer in this short interim period."

Commenting on his appointment, Tony Gardiner said:

"Avacta's Affimer® technology is very compelling and has great potential as a therapeutic platform and in the form of innovative research tools. I am impressed with the Company and its plans, and I look forward to working with the leadership team to build the business and to help it reach its full potential."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Tony Peter Gardiner, aged 44 years, has been a director of the following companies during the five years preceding the date of this announcement:

Past directorships Fusion IP plc Fusion IP Two Limited Fusion IP Cardiff Limited Fusion IP Sheffield Limited Fusion IP Nottingham Limited

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Enquiries:

Avacta Group plc
Alastair Smith, Chief Executive Officer
Tel: +44 (0) 844 414 0452
Craig Slater, Chief Financial Officer www.avacta.com

Numis Securities Limited
Tel: +44 (0) 207 260 1000
www.numiscorp.com
Michael Meade / Freddie Barnfield – Nominated Adviser
James Black – Corporate Broking

WG Partners
David Wilson
Nigel Barnes
Claes Spang
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk

Media Enquiries
FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0) 203 727 1000
[email protected]

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i